Increasing suction pressure during endotracheal suctioning increases the volume of suctioned secretions,but not procedure-related complications: A comparative study in open system endotracheal suctioning

ObjectivesTo compare the effect of three different suction pressures (80 mmHg, 150 mmHg, 250 mmHg) with the open system suction method in terms of the volume of secretions and complications development in intubated intensive care patients.Research methodology/designThis study was planned as a prospective, experimental, self-controlled design. The study sample included 47 patients. Data were collected using a data collection and patient follow-up form from patient records.SettingSingle adult intensive care unit in a university hospital.ResultsFifty five percent of the patients were male, 61.7% were older than 65 years and 38.32% had lung infection. The amount of suctioned secretions tended to increase significantly with increasing negative pressure and there was a significant difference between the pressures in terms of the median volume of suctioned secretions (p < 0.001). There was no significant difference between the suction pressures in terms of oxygen desaturation, hypertension rates (p > 0.05). Tachycardia, bradycardia, hypoxaemia, tracheal mucosal damage or mucosal bleeding were not observed during suctioning with three different suction pressures.ConclusionIt may be assumed that 250 mmHg suction pressure, via compliance with open system suction method related procedures, is being more effective and equally safe for secretion cleaning in comparison to the 80 and 150 mmHg suction pressures.     

前列腺纤维化的研究进展

部分表现为下尿路症状(LUTS)的患者前列腺体积并不大,有证据支持前列腺纤维化是除BPH、平滑肌功能障碍之外,导致LUTS的原因之一。研究表明,前列腺纤维化的发生与各种原因导致的炎症、缺血缺氧、药物相关,具体机制涉及肌成纤维细胞的分化、聚集和活化。因此,抗炎、抗纤维化可能是治疗LUTS的潜在作用靶点。本文就前列腺纤维化的成因、诊断、与LUTS的关系及治疗进展作一综述。     

应用专科护理质量指标管理提高结肠镜诊疗病人肠道准备的合格率

[目的]探讨专科护理质量指标管理在提高结肠镜诊疗病人肠道准备合格率的作用。[方法]选取2018年3月-2018年6月行结肠镜检查的341例病人为对照组,实施常规肠道准备,2018年7月-2018年10月行结肠镜检查的401例病人为观察组,运用专科护理质量指标进行管理,落实包括建立标准饮食单、规范的泻药服用及方法、分时段健康教育及图片式粪便观察等护理措施及相应质控查检表等相关内容,比较两组病人肠道准备合格率及耐受度。[结果]观察组较对照组病人的肠道准备合格率及耐受度均有明显提高,差异有统计学意义(P<0.01)。[结论]应用专科护理质量指标管理,显著提高了病人肠道准备的合格率及病人的耐受度,体现了标准化肠道准备过程中人性化关怀,同时提升了专科护理质量及护士的专科综合能力。     

小儿宝泰康颗粒治疗小儿急性上呼吸道感染的临床研究

目的:研究观察小儿宝泰康颗粒治疗小儿急性上呼吸道感染的临床疗效及安全性评价。方法:选取2018年1月至2019年1月山东省立医院儿科门诊收治的急性上呼吸道感染患儿86例作为研究对象,按照就诊先后顺序编号分为对照组和观察组,每组43例。对照组给予小儿豉翘清热颗粒治疗,观察组给予小儿宝泰康颗粒治疗。对2组患儿的临床疗效、症状消退时间、血清炎性反应因子水平、不良反应发生率等进行统计比较。结果:治疗后观察组总有效率高于对照组,差异有统计学意义(P<0.05),且观察组痊愈率高于对照组,差异有统计学意义(P<0.05),显效率低于对照组,差异有统计学意义(P<0.05);有效率2组较为相近,差异无统计学意义(P>0.05),无效率低于对照组,差异有统计学意义(P<0.05)。治疗后观察组发热、咳嗽、鼻塞流涕、咽喉肿痛、脘腹胀满、食欲不振等症状消退时间均短于对照组,组间比较,差异有统计学意义(P<0.05)。治疗后2组患儿的血清白细胞介素-6(IL-6)、血清白细胞介素-18(IL-18)、肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)水平均有显著降低,差异有统计学意义(P<0.05),且观察组各项指标水平均低于对照组,差异有统计学意义(P<0.05)。对照组发生水样便腹泻2例,腹痛1例,观察组未出现不良反应,组间比较,差异无统计学意义(P>0.05)。结论:小儿宝泰康颗粒治疗小儿急性上呼吸道感染的临床疗效显著,能够缩短患儿的症状消退时间,降低患儿自身的炎性反应水平,治疗安全性良好,值得临床推荐。     

Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort study

ABSTRACT

Objectives: Limited evidence has suggested that cefoperazone-sulbactam causes coagulation disorders and bleeding.

Methods: The authors conducted a retrospective study to compare patients receiving cefoperazone-sulbactam versus those treated with cefoperazone-tazobactam or ceftazidime. Propensity-score matching was used to explore whether treatment with cefoperazone-sulbactam increased the risk of prothrombin time (PT) prolongation, coagulation disorders, and bleeding, or decreased platelets (PLT).

Results: The cohort included 23,242 patients. Among patients receiving cefoperazone-sulbactam, the risk of PT prolongation, coagulation disorders, decreased PLT, and bleeding was 5.3%, 9.2%, 15.7%, and 4.2%, respectively. Propensity-score matching analyses suggested that cefoperazone-sulbactam increased the risk of PT prolongation (aOR 2.26, 95% CI 1.61–3.18), coagulation disorders (aOR 1.81, 95% CI 1.43–2.30), and decreased PLT (aOR 1.46, 95% CI 1.25–1.72), but not increase bleeding (aOR 1.05, 95% CI 0.79–1.40) compared with ceftazidime. Patients receiving cefoperazone-sulbactam had higher risk of PT prolongation (aOR 1.53, 95% CI 1.11–2.10), coagulation disorders (aOR 1.53, 95% CI 1.21–1.95), but not decreased PLT (aOR 0.93, 95% CI 0.81–1.07) or bleeding (aOR 1.11, 95% CI 0.87–1.42), compared with those receiving cefoperazone-tazobactam.

Conclusion: Cefoperazone-sulbactam may be associated with a higher risk of PT prolongation and coagulation disorders compared with cefoperazone-tazobactam and ceftazidime.     

Resultados preliminares de un trabajo multicéntrico a nivel nacional para el tratamiento de STUI secundario a hiperplasia benigna de próstata mediante el sistema con vapor de agua Rezūm®

Introduction and objectiveRezūm® system is a minimally invasive transurethral therapy that uses convective water vapor energy to ablate prostatic tissue. The objective is to report 1-year functional and security outcomes obtained by using this technique in real clinical practice.Material and methodsProspective study conducted in 5 Spanish hospitals for the treatment of LUTS secondary to BPH using the Rezūm® system. Patients with prostatic medium lobe (ML) and urethral catheter carriers were also included. Pre- and post-operative data were collected using IPSS, IIEF-5 and QoL questionnaires, flowmetry and post-void residual volume. Complications and retreatment rate at one-year follow-up were also reported.Results137 patients, including 64 with ML and 10 patients with urinary retention were treated. Median prostate volume was 50 cm³ (15-131). At 3 months follow-up, significant improvement was observed in IPSS (?6,37 points), Qmax (+4,95 mL/s) and QoL (?1,29); and was maintained until 12 months: ?10,78 points, +4,62 mL/s and ?2,73 respectively (p < 0.001). No significant changes were observed in the sexual sphere. All complications were mild (≤ Clavien II). Retreatment rate at one year was 4%.ConclusionShort-term results of this technique are promising, showing improvement in terms of functional outcomes, with no impact on the sexual sphere or complications. Longer term follow-up should include treatment durability and comparison to standard BPH treatments.     

补中益气汤联合耳穴贴压对消化道肿瘤癌因性疲乏患者免疫功能及血清皮质醇的影响

目的:探讨补中益气汤联合耳穴贴压对消化道肿瘤癌因性疲乏患者免疫功能及血清皮质醇的影响。方法:选择消化道肿瘤癌因性疲乏患者92例,以随机数字表法分为两组,各46例。对照组常规治疗加耳穴贴压,观察组在对照组基础上加用补中益气汤。对比两组临床疗效、疲劳症状、生活质量、免疫功能指标、血清皮质醇及不良反应。结果:观察组总有效率为80.43%,高于对照组的60.87%(P<0.05)。治疗后两组患者PFS、CD₈⁺均降低,但观察组降低水平更大; 治疗后两组QLQ-C30、CD₃⁺、CD₄⁺及Cor水平均明显升高,且观察组升高幅度更大(P<0.05)。治疗期间对照组未出现明显不良反应,观察组出现2例,组间比较差异无统计学意义(P>0.05)。对照组平均生存时间为(11.80±0.62)个月,观察组平均生存时间为(14.47±0.67)个月,两组比较差异有统计学意义(P<0.05)。结论:补中益气汤联合耳穴贴压可提高消化道肿瘤癌因性疲乏患者临床疗效,延长患者生存期,改善疲劳症状、免疫功能指标,提高生活质量及皮质醇水平。